StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Investment analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK – Get Rating) in a report released on Friday. The firm set a “sell” rating on the medical research company’s stock.

Separately, HC Wainwright cut their target price on Check-Cap from $15.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, April 5th.

Check-Cap Trading Down 0.7 %

Shares of Check-Cap stock opened at $1.47 on Friday. The firm has a market cap of $7.09 million and a P/E ratio of -0.66. Check-Cap has a 12 month low of $1.22 and a 12 month high of $9.20. The stock’s fifty day moving average price is $1.50 and its 200-day moving average price is $2.73.

Check-Cap (NASDAQ:CHEK – Get Rating) last announced its quarterly earnings results on Friday, March 31st. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.04. Analysts forecast that Check-Cap will post -1.8 earnings per share for the current year.

Hedge Funds Weigh In On Check-Cap

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its holdings in Check-Cap by 363.4% in the second quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock worth $69,000 after acquiring an additional 176,207 shares in the last quarter. Sabby Management LLC acquired a new stake in Check-Cap in the first quarter worth about $91,000. Citadel Advisors LLC boosted its holdings in Check-Cap by 51.2% in the third quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after acquiring an additional 47,868 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Check-Cap in the first quarter worth about $57,000. Hedge funds and other institutional investors own 17.59% of the company’s stock.

Check-Cap Company Profile

(Get Rating)

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.